-
-
-
[1] 第二届全国难治性白血病研讨会.关于难治性白血病诊断标准的建议(草案)[J].白血病,2000,9(1):63-63.
[2] 中华医学会血液学分会,中国抗癌协会血液肿瘤专业委员会.中国成人急性淋巴细胞白血病诊断与治疗专家共识[J].中华血液学杂志,2012,33(9):789-792.
[3] 赵万红,张王刚,曹星梅,等.MEAD方案治疗难治复发性成年人急性淋巴细胞白血病[J].白血病.淋巴瘤,2010,19(6):349-351.
[4] ROBAK P,ROBAK T.Older and new purine nucleoside analogs for patients with acute leukemias[J].Cancer Treat Rev,2013,doi:10.1016/j.ctrv.2013.03.006.[Epub ahead of print].
[5] MIANO M,PISTORIO A,PUTTI M C,et al.Clofarabine,cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients[J].Leuk Lymphoma,2012,53:1693-1698.
[6] COOPER T M,RAZZOUK B I,GERBING R,et al.Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523)[J].Pediatric Blood Cancer,2013,60:1141-1147.
[7] TRIOCHE P,NELKEN B,MICHEL G,et al.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukemia[J].Exp Hematol Oncol,2012,1:39.
[8] FORCADE E,LEGUAY T,VEY N,et al.Nelarabine for T-cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation:an opportunity to improve survival[J].Biol Blood Marrow Transplant,2013,19:1124-1126.
[9] DU X L,CHEN Q.Recent advancements of bortezomib in acute lymphocytic leukemia treatment[J].Acta Haematol,2013,129:207-214.
[10] BASTIAN L,HOF J,PFAU M,et al.Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53,PI3K/AKT,and NF-κB[J].Clin Cancer Res,2013,19:1445-1457.
[11] FIELDING A K.Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Hematology Am Soc Hematol Educ Program,2011,2011:231-237.
[12] RAETZ E A,BHATLA T.Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?[J].Hematology Am Soc Hematol Educ Program,2012,2012:129-136.
[13] THOMAS D A,O'BRIEN S,FADERL S,et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia[J].J Clin Oncol,2010,28:3880-3889.
[14] CHEVALLIER P,PIGNEUX A,ROBILLARD N,et al.Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients:a pilot series[J].Leuk Res,2012,36:311-315.
[15] 马军.2011年欧洲血液学协会大会有关抗CD20单克隆抗体治疗淋巴瘤和慢性淋巴细胞白血病的热点报道[J].白血病.淋巴瘤,2011,20(8):449-450.
[16] KANTARJIAN H,THOMAS D,JORGENSEN J,et al.Inotuzumab ozogamicin,an anti-CD22-calecheamicin conjugate,for refractory and relapsed acute lymphocytic leukemia:a phase 2 study[J].Lancet Oncol,2012,13:403-411.
[17] LITZOW M R.Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia[J].Am Soc Clin Oncol Educ Book,2013,2013:294-299.
[18] HOELZER D.Novel antibody-based therapies for acute lymphoblastic leukemia[J].Hematology Am Soc Hematol Educ Program,2011,2011:243-249.
[19] SPYRIDONIDIS A,LABOPIN M,SCHMID C,et al.Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation[J].Leukemia,2012,26:1211-1217.
-
计量
- 文章访问数: 40
- PDF下载数: 747
- 施引文献: 0
下载: